Potential activity of camel milk-amylase and lactoferrin against hepatitis C virus infectivity in HepG2 and lymphocytes

Hepatitis Monthly

Volumn 8, Issue 2, 2008, Pages 101-109

  El Fakharany, Esmail M ^a   Tabll, Ashraf ^b   El Wahab, Abeer Abd ^a   Haroun, Bakry M ^c   Redwan, El Rashdy M ^a  

^a Universities and Research centers District   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c Assiut Branch   (Egypt)

Author keywords

Amylase; Camel milk; Hepatitis C; In Vitro Assay; Inhibition; Lactoferrin

Indexed keywords

AMYLASE; LACTOFERRIN; MILK PROTEIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CAMEL; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

EID: 46649119727     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Yokoyama Y, Kuramitsu Y, Takashima M, Iizuka N, Toda T, Terai S, et al. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics 2004; 4: 2111-6.
2. Miller RH, Purcell RH. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A 1990; 87: 2057-61.
3. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 1994; 75: 1053-61.
4. O'Brien TR, Kirk G, Zhang M. Hepatocellular carcinoma: paradigm of preventive oncology. Cancer J 2004; 10: 67-73.
5. Tanaka J, Yoshizawa H. A national project for the management of viral hepatitis toward prevention of hepatocellular carcinoma in Japan (in Japanese). Gan To Kagaku Ryoho 2004; 31: 864-70.
6. Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P. Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 2002; 277: 17713-21.
7. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, et al. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol 2005; 43: 1902-9.
8. Redwan el RM, Larsen NL, Wilson IA. Simplified procedure for elimination of co-purified contaminant proteins from human colostrums IgA1. J Egypt Ger Soc Zool 2003; 40A: 251-60.
9. Cohen MS, Britigan BE, French M, Bean K. Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implications for infection with Neisseria gonorrhoeae. Am J Obstet Gynecol 1987; 157: 1122-5.
10. Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, The TH, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995; 172: 380-8.
11. Jenssen H. Anti herpes simplex virus activity of lactoferrin/ lactoferricin - an example of antiviral activity of antimicrobial protein/peptide. Cell Mol Life Sci 2005; 62: 3002-13.
12. Marchetti M, Trybala E, Superti F, Johansson M, Bergstrom T. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 2004; 318: 405-13.
13. Longhi G, Pietropaolo V, Mischitelli M, Longhi C, Conte MP, Marchetti M, et al. Lactoferrin inhibits early steps of human BK polyomavirus infection. Antiviral Res 2006; 72: 145-52.
14. Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, et al. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 2002; 24: 228.
15. Drobni P, Naslund J, Evander M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res 2004; 64: 63-8.
16. Swart PJ, Kuipers ME, Smit C, Pauwels R, deBethune MP, de Clercq E, et al. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Human Retroviruses 1996; 12: 769-75.
17. Yi M, Kaneko S, Yu DY, Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J Virol 1997; 71: 5997-6002.
18. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201-7.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
21. Lohr HF, Goergen B, Meyer zum Buschenfelde KH, Gerken G. HCV replication in mononuclear cells stimulates anti-HCV-secreting B cells and reflects nonresponsiveness to interferon-alpha. J Med Virol 1995; 46: 314-20.
22. Redwan el RM, Tabll A. Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. J Immunoassay Immunochem 2007; 28: 267-77.
23. Evans EW. Use of milk proteins in formulated foods. In: Hudson BJF, ed. Developments in Food Proteins. London: Applied Science 1982.
24. Fournier C, Duverlie G, Francois C, Schnuriger A, Dedeurwaerder S, Brochot E, et al. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J 2007; 4: 35.
25. Ikeda M, Nozaki A, Sugiyama K, Tanaka T, Naganuma A, Tanaka K, et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 2000; 66: 51-63.
26. Nozaki A, Ikeda M, Naganuma A, Nakamura T, Inudoh M, Tanaka K, et al. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 2003; 278: 10162-73.
27. Wang H, Ye X, Ng TB. First demonstration of an inhibitory activity of milk proteins against human immunodeficiency virus-1 reverse transcriptase and the effect of succinylation. Life Sci 2000; 67: 2745-52.
28. Ng TB, Lam TL, Au TK, Ye XY, Wan CC. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, protease and integrase by bovine milk proteins. Life Sci 2001; 69: 2217-23.
29. Khan JA, Kumar P, Paramasivam M, Yadav RS, Sahani MS, Sharma S, et al. Camel lactoferrin, a transferrin-cumlactoferrin: crystal structure of camel apolactoferrin at 2.6 A resolution and structural basis of its dual role. J Mol Biol 2001; 309: 751-61.
30. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
31. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.
32. Konishi M, Iwasa M, Yamauchi K, Sugimoto R, Fujita N, Kobayashi Y, et al. Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res 2006; 36: 27-32.